论文部分内容阅读
目的:观察吡格列酮联用瑞格列奈治疗2型糖尿病的疗效和安全性。方法:将60例2型糖尿病患者随机分为两组,治疗组采用吡格列酮联用瑞格列奈治疗,对照组单用瑞格列奈治疗,共12周,观察两组治疗前后血糖、血脂、糖化血红蛋白(HbA1c)、空腹胰岛素(FIns)、餐后胰岛素(2hIns)、胰岛素抵抗指数(HOMA-IR)、血压、肝肾功能的变化。结果:治疗组能显著降低血糖、HbA1c、FIns、2hIns、胰岛素抵抗指数(HOMA-IR)(P<0.01),并能降低患者血脂(P<0.05),血压影响不大,且无肝肾功能损害发生。结论:吡格列酮联用瑞格列奈治疗2型糖尿病有明显疗效,且安全性好。
Objective: To observe the efficacy and safety of pioglitazone combined with repaglinide in type 2 diabetes mellitus. Methods: Sixty patients with type 2 diabetes were randomly divided into two groups. The treatment group was treated with pioglitazone combined with repaglinide, the control group with repaglinide alone for 12 weeks. The levels of blood glucose, blood lipid, (HbA1c), fasting insulin (FIns), postprandial insulin (2hIns), insulin resistance index (HOMA-IR), blood pressure, liver and kidney function changes. Results: The blood glucose, HbA1c, FIns, 2hIns and HOMA-IR (P <0.01) were significantly lower in the treatment group than those in the control group (P <0.05) Damage occurs. Conclusion: Pioglitazone combined with repaglinide has obvious curative effect on type 2 diabetes and its safety is good.